BACKGROUND: IL-15 is a proinflammatory and antiapoptotic T-cell growth factor that plays an important role in a variety of autoimmune disorders and transplant rejection. To inhibit IL-15 function and to target IL-15 receptor (IL-15R) bearing cells, we have generated a unique lytic antagonistic mutant IL-15/Fc fusion protein (mIL-15/Fc). METHODS: In this study, we further examined the efficacy of mIL-15/Fc in preventing allograft rejection cross minor and major histocompatibility barriers. RESULTS: A short-course treatment with mIL-15/Fc fusion protein is sufficient to prevent cardiac allograft rejection and induce antigen-specific tolerance in minor histocompatibility complex-mismatched recipients, and permit prolonged cardiac allograft survival in fully MHC mismatched recipients. In addition, mIL-15/Fc treatment, in combination with a suboptimal dose of anti-CD154 antibody, confers permanent cardiac allograft engraftment in a fully MHC-mismatched mouse strain combination. In a murine islet allograft model, mIL-15/Fc monotherapy is capable to permit permanent allograft survival in 50% fully MHC-mismatched recipients. CONCLUSION: Immunochemistry studies demonstrated that prolonged graft survival was accompanied by reduced intragraft mononuclear cell infiltration and pro-inflammatory cytokine gene expression in the mIL-15/Fc treated recipients. Moreover, parallel experiments employing a mutated nonlytic IgG2a Fc demonstrate that the Fc portion of mIL-15/Fc contributes to the overall efficacy of the molecule in vivo.
BACKGROUND:IL-15 is a proinflammatory and antiapoptotic T-cell growth factor that plays an important role in a variety of autoimmune disorders and transplant rejection. To inhibit IL-15 function and to target IL-15 receptor (IL-15R) bearing cells, we have generated a unique lytic antagonistic mutant IL-15/Fc fusion protein (mIL-15/Fc). METHODS: In this study, we further examined the efficacy of mIL-15/Fc in preventing allograft rejection cross minor and major histocompatibility barriers. RESULTS: A short-course treatment with mIL-15/Fc fusion protein is sufficient to prevent cardiac allograft rejection and induce antigen-specific tolerance in minor histocompatibility complex-mismatched recipients, and permit prolonged cardiac allograft survival in fully MHC mismatched recipients. In addition, mIL-15/Fc treatment, in combination with a suboptimal dose of anti-CD154 antibody, confers permanent cardiac allograft engraftment in a fully MHC-mismatched mouse strain combination. In a murine islet allograft model, mIL-15/Fc monotherapy is capable to permit permanent allograft survival in 50% fully MHC-mismatched recipients. CONCLUSION: Immunochemistry studies demonstrated that prolonged graft survival was accompanied by reduced intragraft mononuclear cell infiltration and pro-inflammatory cytokine gene expression in the mIL-15/Fc treated recipients. Moreover, parallel experiments employing a mutated nonlytic IgG2aFc demonstrate that the Fc portion of mIL-15/Fc contributes to the overall efficacy of the molecule in vivo.
Authors: Xin Xiao Zheng; Alberto Sánchez-Fueyo; Masayuki Sho; Christoph Domenig; Mohamed H Sayegh; Terry B Strom Journal: Immunity Date: 2003-10 Impact factor: 31.745
Authors: Y S Kim; W Maslinski; X X Zheng; A C Stevens; X C Li; G H Tesch; V R Kelley; T B Strom Journal: J Immunol Date: 1998-06-15 Impact factor: 5.422
Authors: J Strehlau; M Pavlakis; M Lipman; M Shapiro; L Vasconcellos; W Harmon; T B Strom Journal: Proc Natl Acad Sci U S A Date: 1997-01-21 Impact factor: 11.205
Authors: T van Gelder; C C Baan; A H Balk; C J Knoop; C T Holweg; P van der Meer; B Mochtar; P E Zondervan; H G Niesters; W Weimar Journal: Transplantation Date: 1998-02-15 Impact factor: 4.939
Authors: C C Baan; C J Knoop; T van Gelder; C T Holweg; H G Niesters; T J Smeets; F van der Ham; P E Zondervan; L P Maat; A H Balk; W Weimar Journal: Transplantation Date: 1999-03-27 Impact factor: 4.939
Authors: X X Zheng; A W Steele; W W Hancock; A C Stevens; P W Nickerson; P Roy-Chaudhury; Y Tian; T B Strom Journal: J Immunol Date: 1997-05-01 Impact factor: 5.422
Authors: K H Grabstein; J Eisenman; K Shanebeck; C Rauch; S Srinivasan; V Fung; C Beers; J Richardson; M A Schoenborn; M Ahdieh Journal: Science Date: 1994-05-13 Impact factor: 47.728
Authors: Richard L Wong; Bai Liu; Xiaoyun Zhu; Lijing You; Lin Kong; Kai-Ping Han; Hyung-Il Lee; Pierre-Andre Chavaillaz; Moonsoo Jin; Yi Wang; Peter R Rhode; Hing C Wong Journal: Protein Eng Des Sel Date: 2010-12-21 Impact factor: 1.650
Authors: Yuta Asano; Joe Daccache; Dharmendra Jain; Kichul Ko; Andrew Kinloch; Margaret Veselits; Donald Wolfgeher; Anthony Chang; Michelle Josephson; Patrick Cunningham; Anat Tambur; Aly A Khan; Shiv Pillai; Anita S Chong; Marcus R Clark Journal: Nat Commun Date: 2021-07-16 Impact factor: 17.694